Plus Therapeutics Inc (USA) (OQ:PSTV)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4200 Marathon Blvd Ste 200
AUSTIN TX 78756-3433
Tel: N/A
Website: www.plustherapeutics.com
IR: See website
<
Key People
Marc H. Hedrick
President, Chief Executive Officer, Director
Andrew Sims
Chief Financial Officer
Pius Maliakal
Vice President - Clinical Operations
Norman Lafrance
Chief Medical Officer
   
Business Overview
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company's Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Financial Overview
For the fiscal year ended 31 December 2023, Plus Therapeutics Inc (USA) revenues increased from $224K to $4.9M. Net loss decreased 34% to $13.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Expense decrease of 44% to $395K (expense), Interest Income increase from $147K to $400K (income).
Employees: 20 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $12.42M as of Dec 31, 2023
Annual revenue (TTM): $4.91M as of Dec 31, 2023
EBITDA (TTM): -$12.69M as of Dec 31, 2023
Net annual income (TTM): -$13.32M as of Dec 31, 2023
Free cash flow (TTM): -$13.01M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 4,276,082 as of Feb 26, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.